Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06280235 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT06280235 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 243 participants.
The verdict
NCT06280235, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2 to 4 and a half months. During this time, they visit the study site at least 6 times. At the visits, doctors ask participants about their symptoms. The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants.
Interventions
- DRUG Placebo
- DRUG BI 1569912
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06280235
The ClinicalTrials.gov registry entry for NCT06280235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06280235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06280235 about?
NCT06280235 is a clinical study titled "A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine". This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their stand...
What is the current status of trial NCT06280235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2024-03-27. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06280235?
The interventions under investigation include: Placebo (DRUG), BI 1569912 (DRUG).
Who is sponsoring clinical trial NCT06280235?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.